Brokerages expect Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) to post ($0.22) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Galmed Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.17). Galmed Pharmaceuticals posted earnings of ($0.17) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 29.4%. The company is expected to announce its next earnings results on Wednesday, May 8th.

On average, analysts expect that Galmed Pharmaceuticals will report full-year earnings of ($1.30) per share for the current financial year, with EPS estimates ranging from ($1.74) to ($0.72). For the next year, analysts forecast that the company will report earnings of ($1.68) per share, with EPS estimates ranging from ($2.02) to ($1.34). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Galmed Pharmaceuticals.

Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). Galmed Pharmaceuticals had a negative return on equity of 18.55% and a negative net margin of 423.62%.

Several brokerages have recently weighed in on GLMD. HC Wainwright reiterated a “buy” rating on shares of Galmed Pharmaceuticals in a report on Thursday. Cantor Fitzgerald reiterated a “buy” rating and issued a $59.00 price target on shares of Galmed Pharmaceuticals in a report on Wednesday. ValuEngine upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Finally, Zacks Investment Research downgraded Galmed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 28th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $32.78.

Shares of NASDAQ GLMD traded down $0.29 during midday trading on Thursday, hitting $8.15. The company’s stock had a trading volume of 189,736 shares, compared to its average volume of 114,986. Galmed Pharmaceuticals has a 12-month low of $4.84 and a 12-month high of $27.06. The company has a market cap of $129.67 million, a price-to-earnings ratio of -8.32 and a beta of 2.68.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in Galmed Pharmaceuticals during the 4th quarter worth $33,000. Northern Trust Corp boosted its position in Galmed Pharmaceuticals by 16.3% during the 4th quarter. Northern Trust Corp now owns 12,215 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,715 shares in the last quarter. Trellus Management Company LLC bought a new stake in Galmed Pharmaceuticals during the 3rd quarter valued at $227,000. Wells Fargo & Company MN bought a new stake in Galmed Pharmaceuticals during the 3rd quarter valued at $297,000. Finally, ETF Managers Group LLC boosted its position in Galmed Pharmaceuticals by 48.9% during the 4th quarter. ETF Managers Group LLC now owns 34,656 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 11,382 shares in the last quarter. Institutional investors own 48.10% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Read More: QQQ ETF

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.